Key result
ORBIT best predicts major bleeding in AF patients with cancer with ~0.81 AUC.
Why the study?
The association between cancer types and bleeding in AF is scarcely investigated, and the performance of bleeding risk scores in these patients remains unclear.
Do the HAS-BLED, ATRIA, and ORBIT bleeding risk scores accurately predict bleeding events in hospitalized patients with atrial fibrillation and cancer?
Cohort (n=399,344)
Yes
Do the HAS-BLED, ATRIA, and ORBIT bleeding risk scores accurately predict bleeding events in hospitalized patients with atrial fibrillation and cancer?
Effect estimate: AUC 0.805
In patients with atrial fibrillation and cancer, the ORBIT score demonstrated the highest predictive value for major bleeding compared to the HAS-BLED and ATRIA scores.
Bleeding risk varies by cancer type in AF; leaves open whether HAS-BLED, ATRIA, or ORBIT require cancer-specific recalibration.
Background The association between cancer types and specific bleeding events in patients with atrial fibrillation has been scarcely investigated. Also, the performance of bleeding risk scores in this high-risk subgroup of patients is unclear. We investigated the rate of any bleeding, intracranial hemorrhage, major bleeding, and gastrointestinal bleeding according to cancer types in patients with atrial fibrillation. We also tested the predictive value of HAS-BLED, ATRIA, and ORBIT bleeding risk scores. Methods and Results Observational retrospective cohort study including hospitalized patients with atrial fibrillation and cancer from the French National Hospital Discharge Database (Programme de Medicalisation des Systemes d'Information) from January 2010 to December 2019. Major bleeding was defined according to Bleeding Academic Research Consortium definitions. Patients with HAS-BLED ≥3, ATRIA ≥5, or ORBIT ≥4 were classified as at high bleeding risk. Receiver operating characteristic analysis for each score against any bleeding, major bleeding, gastrointestinal bleeding, and intracranial hemorrhage was performed. Areas under the curve (AUCs) were then compared. We included 399 344 patients. Mean age was 77.9±10.2 years, and 63.2% were men. The highest intracranial hemorrhage rates were found in leukemia (1.89%/year), myeloma (1.52%/year), lymphoma and liver (1.45%/year), and pancreas cancer (1.41%/year). Receiver operating characteristic analysis showed that ORBIT score predicted best for any bleeding. In addition, ORBIT score ≥4 had the highest predictivity for major bleeding (AUC, 0.805), followed by HAS-BLED ≥3 and ATRIA ≥5 (AUCs, 0.716 and 0.700, respectively). HAS-BLED and ORBIT performed best for intracranial hemorrhage (AUCs, 0.744 and 0.742 for continuous scores, respectively), better than ATRIA (AUC, 0.635). For gastrointestinal bleeding, ORBIT ≥4 had the highest predictivity (AUC, 0.756), followed by the HAS-BLED ≥3 (AUC, 0.702) and ATRIA ≥5 (AUC, 0.662). Conclusions Some cancer types carry a greater bleeding risk in patients with atrial fibrillation. The identification and management of modifiable bleeding risk factors is crucial in these patients, as well as to flag up high bleeding risk patients for early review and follow-up.
No takes yet. Share an insight, caveat, or question.
Pastori et al. (2022) conducted a cohort in Atrial fibrillation and cancer (n=399,344). HAS-BLED, ORBIT, and ATRIA bleeding risk scores was evaluated on Predictive value for major bleeding (AUC 0.805). The ORBIT bleeding risk score demonstrated the highest predictive value for major bleeding (AUC 0.805) and gastrointestinal bleeding (AUC 0.756) in patients with atrial fibrillation and cancer.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: